Atezolizumab (atezo) plus nab-paclitaxel (nab-pac) in metastatic triple-negative breast cancer (mTNBC): 2-year update from a ph Ib trial

被引：2
|
作者：
Pohlmann, Paula R. [1 ]
Diamond, Jennifer R. [2 ]
Hamilton, Erika [3 ,4 ]
Tolaney, Sara M. [5 ]
Zhang, Wei [6 ]
Iizuka, Koho [6 ]
Foster, Paul [6 ]
Molinero, Luciana [6 ]
Funke, Roel [6 ]
Adams, Sylvia [7 ]
机构：
[1] MedStar Georgetown Univ Hosp, Lombardi Comprehens Canc Ctr, Washington, DC USA
[2] Univ Colorado, Ctr Canc, Aurora, CO USA
[3] Sarah Cannon Res Inst, Nashville, TN USA
[4] Tennessee Oncol, Nashville, TN USA
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Genentech Inc, San Francisco, CA 94080 USA
[7] NYU, Langone Med Ctr, New York, NY USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-CT028
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT028
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Pilot study of carboplatin, nab-paclitaxel and pembrolizumab for metastatic triple-negative breast cancer (ongoing clinical trial)
    Baar, J.
    Abraham, J.
    Silverman, P.
    Budd, G. T.
    Vinayak, S.
    Varadan, V.
    Moore, H.
    Montero, A.
    Fu, P.
    CANCER RESEARCH, 2017, 77
  • [32] IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab plus nab-paclitaxel vs placebo plus nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer
    Iwata, H.
    Emens, L.
    Adams, S.
    Barrios, C. H.
    Dieras, V.
    Loi, S.
    Rugo, H. S.
    Schneeweiss, A.
    Winer, E. P.
    Patel, S.
    Henschel, V.
    Swat, A.
    Kaul, M.
    Molinero, L.
    Chui, S. S.
    Schmid, P.
    ANNALS OF ONCOLOGY, 2020, 31 : S1261 - S1262
  • [33] Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer
    Yuan, Yuan
    Lee, Jin Sun
    Yost, Susan E.
    Li, Sierra Min
    Frankel, Paul H.
    Ruel, Christopher
    Schmolze, Daniel
    Robinson, Kim
    Tang, Aileen
    Martinez, Norma
    Stewart, Daphne
    Waisman, James
    Kruper, Laura
    Jones, Veronica
    Menicucci, Andrea
    Uygun, Sahra
    Yoder, Erin
    van der Baan, Bastiaan
    Yim, John H.
    Yeon, Christina
    Somlo, George
    Mortimer, Joanne
    ONCOLOGIST, 2021, 26 (03): : E382 - E393
  • [34] Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study
    Emens, Leisha A.
    Molinero, Luciana
    Loi, Sherene
    Rugo, Hope S.
    Schneeweiss, Andreas
    Dieras, Veronique
    Iwata, Hiroji
    Barrios, Carlos H.
    Nechaeva, Marina
    Anh Nguyen-Duc
    Chui, Stephen Y.
    Husain, Amreen
    Winer, Eric P.
    Adams, Sylvia
    Schmid, Peter
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2021, 113 (08): : 1005 - 1016
  • [35] Safety and clinical activity of atezolizumab (anti-PDL1) in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer
    Adams, S.
    Diamond, J.
    Hamilton, E.
    Pohlmann, P.
    Tolaney, S.
    Molinero, L.
    Zou, W.
    Liu, B.
    Waterkamp, D.
    Funke, R.
    Powderly, J.
    CANCER RESEARCH, 2016, 76
  • [36] First-Line Treatment With Atezolizumab Plus Nab-Paclitaxel for Advanced Triple-Negative Breast Cancer A Cost-Effectiveness Analysis
    Weng, Xiuhua
    Huang, Xiaoting
    Li, Hongchao
    Lin, Shen
    Rao, Xin
    Guo, Xianzhong
    Huang, Pinfang
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2020, 43 (05): : 340 - 348
  • [37] Weekly nab-paclitaxel (nab-P) plus gemcitabine (gem) or carboplatin (carbo) vs gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC) in a phase 2/3 trial (tnAcity).
    Yardley, Denise A.
    Cortes, Javier
    Coleman, Robert E.
    Conte, Pier Franco
    Brufsky, Adam
    O'Shaughnessy, Joyce
    Wright, Gail Lynn Shaw
    Eakle, Janice F.
    Wilks, Sharon
    Shtivelband, Mikhail
    Young, Robyn R.
    Bengala, Carmelo
    Li, Huiling
    Miller, Julie Ann
    Barton, Debora
    Harbeck, Nadia
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [38] Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions
    Kagihara, Jodi A.
    Andress, Michelle
    Diamond, Jennifer R.
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2020, 5 (02): : 59 - 65
  • [39] Subgroup analysis of IMpassion130: Atezolizumab plus nab-paclitaxel (nab-P) in patients (pts) with advanced triple-negative breast cancer (TNBC) in Asian countries
    Iwata, H.
    Im, S-A.
    Sohn, J.
    Jung, K. H.
    Im, Y-H.
    Lee, K. S.
    Inoue, K.
    Tamura, K.
    Wong, A.
    Emens, L. A.
    Barrios, C. H.
    Adams, S.
    Schneeweiss, A.
    Dieras, V.
    Winer, E. P.
    Chui, S. Y.
    Henschel, V.
    Rugo, H. S.
    Loi, S.
    Schmid, P.
    ANNALS OF ONCOLOGY, 2019, 30
  • [40] randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer
    Chen, Nan
    Saha, Poornima
    Rampurwala, Murtuza M.
    Kamaraju, Sailaja
    Hahn, Olwen Mary
    Howard, Frederick Matthew
    Fleming, Gini F.
    Matossian, Margarite
    Freeman, Jincong Q.
    Karrison, Theodore
    Conzen, Suzanne D.
    Nanda, Rita
    Stringer-Reasor, Erica Michelle
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345